CLINICAL USE OF ARTERIAL PULSE TRACING ANALYSIS. CHANGE IN PULSE CONTOUR FOLLOWING SURGICAL CORRECTION OF A PATENT DUCTUS ARTERIOSUS.
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Pulsatile and nonpulsatile blood flow have been intensely studied for cardiopulmonary bypass (CPB), isolated organ perfusion, and myocardial preservation. Although early studies differed, later ones have shown the benefits of pulsatile flow. Kidney function, lymph flow, and oxygen consumption are increased during pulsatile perfusion. Also, nonpulsatile CPB increases total peripheral resistance and mean arterial pressure, which are related to time of perfusion. Theories to account for the superiority of pulsatile flow include: (1) "vascular shocks" causing physical displacement of tissues, which changes the boundary layer of interstitial fluid around cell membranes and enhances diffusion ;(2) increased lymph movement during pulsatile flow; and (3) pulsatile energy ensuring the patency of the vascular beds and preventing shunting. New methods to create pulsatile flow and their adaptation to the standard roller pump are discussed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Methotrexate and dactinomycin are efficient drugs in the treatment of patients with low-risk gestational trophoblastic neoplasia (LRGTN). To compare the effectiveness of these two drugs in LRGTN, 46 patients were randomised to receive weekly intramuscular methotrexate at 30 mg/m(2) (n = 28) or intravenous dactinomycin at 1.25 mg/m(2) every 2 weeks (n = 18). Fourteen patients (50%) in the methotrexate group and 16 patients (89%) in the dactinomycin group achieved complete response. Greater patient convenience and a lower number of required visits make dactinomycin superior to other alternatives.